IGI Laboratories announced it has received approval from the FDA for its Abbreviated New Drug Application (ANDA) for Lidocaine HCl USP 4% Topical Solution. This marks the company’s first ANDA approval from the FDA.
Lidocaine HCl solution is indicated for the production of topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract. Lidocaine reversibly blocks nerve conduction by reducing membrane permeability to sodium, producing a local analgesic effect.
For more information call (856) 697-1441 or visit IGILabs.com.